Trial Profile

A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rimiducid (Primary) ; Rivogenlecleucel (Primary)
Indications Acute myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Pharmacokinetics
Sponsors Bellicum Pharmaceuticals

10 Jul 2022 Planned End Date changed from 1 Jul 2035 to 1 Sep 2035.
10 Jul 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Sep 2022.
01 Oct 2020 Planned End Date changed from 1 Mar 2035 to 1 Jul 2035.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com